Page 66 - Read Online

Happel et al. J Cancer Metastasis Treat 2020;6:32 I http://dx.doi.org/10.20517/2394-4722.2020.71 Page 17 of 18

22. Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of
colorectal cancer patients as circulating biomarkers. World J Surg 2004;28:721-6.
23. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
24. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov
2014;4:650-61.
25. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol
2011;192:373-82.
26. Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E. Detection and monitoring of cell-free DNA in blood of patients with colorectal
cancer. Ann N Y Acad Sci 2008;1137:190-6.
27. Neumann MHD, Bender S, Krahn T, Schlange T. ctDNA and CTCs in liquid biopsy-current status and where we need to progress.
Comput Struct Biotechnol J 2018;16:190-5.
28. Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, et al. Dissecting the multicellular ecosystem of metastatic melanoma by
single-cell RNA-seq. Science 2016;352:189-96.
29. Ramalingam N, Jeffrey SS. Future of liquid biopsies with growing technological and bioinformatics studies: opportunities and challenges
in discovering tumor heterogeneity with single-cell level analysis. Cancer J 2018;24:104-8.
30. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation
profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014;25:1729-35.
31. De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martinez-Ricarte F, et al. Cerebrospinal fluid-derived circulating tumour DNA better
represents the genomic alterations of brain tumours than plasma. Nat Commun 2015;6:8839.
32. Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, et al. Multifocal clonal evolution characterized using circulating
tumour DNA in a case of metastatic breast cancer. Nat Commun 2015;6:8760.
33. Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat
Genet 2016;48:1273-8.
34. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, et al. Plasma MicroRNAs as sensitive and specific biomarkers of
tissue injury. Clin Chem 2009;55:1977-83.
35. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. MicroRNA expression profiles classify human cancers. Nature
2005;435:834-8.
36. Driedonks TAP, Nolte-’t Hoen ENM. Circulating y-RNAs in extracellular vesicles and ribonucleoprotein complexes; implications for the
immune system. Front Immunol 2018;9:3164.
37. Argyropoulos C, Wang K, McClarty S, Huang D, Bernardo J, et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes.
PLoS One 2013;8:e54662.
38. Fujita Y, Kuwano K, Ochiya T, Takeshita F. The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer
research. Biomed Res Int 2014;2014:486413.
39. Inns J, James V. Circulating microRNAs for the prediction of metastasis in breast cancer patients diagnosed with early stage disease.
Breast 2015;24:364-9.
40. Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 2011;59:823-31.
41. Huang X, Yuan T, Liang M, Du M, Xia S, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate
cancer. Eur Urol 2015;67:33-41.
42. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and
analytical challenges. Clin Chem 2011;57:833-40.
43. Akers JC, Ramakrishnan V, Yang I, Hua W, Mao Y, et al. Optimizing preservation of extracellular vesicular miRNAs derived from clinical
cerebrospinal fluid. Cancer Biomark 2016;17:125-32.
44. O’Neill CP, Gilligan KE, Dwyer RM. Role of extracellular vesicles (EVs) in cell stress response and resistance to cancer therapy. Cancers
(Basel) 2019;11:136.
45. Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, et al. Predictive and prognostic molecular markers for cancer medicine.
Ther Adv Med Oncol 2010;2:125-48.
46. FDA-NIH biomarker working group. BEST (Biomarkers, endpoints, and other tools) resource. Silver spring (MD): food and drug
administration; 2016.
47. Food and drug administration. CDER biomarker qualification program. Available from: https://www.fda.gov/drugs/drug-development-
tool-ddt-qualification-programs/cder-biomarker-qualification-program. [Last accessed on 7 May 2020].
48. Amur SG, Sanyal S, Chakravarty AG, Noone MH, Kaiser J, et al. Building a roadmap to biomarker qualification: challenges and
opportunities. Biomark Med 2015;9:1095-105.
49. Laurent LC, Abdel-Mageed AB, Adelson PD, Arango J, Balaj L, et al. Meeting report: discussions and preliminary findings on
extracellular RNA measurement methods from laboratories in the NIH extracellular RNA communication consortium. J Extracell Vesicles
2015;4:26533.
50. McKiernan J, Donovan MJ, O’Neill V, Bentink S, Noerholm M, et al. A novel urine exosome gene expression assay to predict high-grade
prostate cancer at initial biopsy. JAMA Oncol 2016;2:882-9.
51. Li F, Yoshizawa JM, Kim KM, Kanjanapangka J, Grogan TR, et al. Discovery and validation of salivary extracellular RNA biomarkers
for noninvasive detection of gastric cancer. Clin Chem 2018;64:1513-21.
52. Mithraprabhu S, Morley R, Khong T, Kalff A, Bergin K, et al. Monitoring tumour burden and therapeutic response through analysis of